Insider · CIK 0001358787
Richard H Deily
cfoofficerother
Files at AGX (ARGAN INC). First filing Jan 10, 2025, latest Jul 31, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $928k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AGX: ARGAN INC
AGXOct 9, 2026 · close 392.61
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | ARGAN INC | $389k 1,604 shares | -17% | +180% from low0% from high | |
| 40Moderate | AGXsell ARGAN INC | $238k 1,565 shares | -17% | +75% from low-17% from high | |
| 56Moderate | ARGAN INC | $300k 2,000 shares | -18% | +77% from low-3% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 30, 2025 | AGX ARGAN INC | MOption exercise Common Stock | +1,604 | $36.78 | $59k | 9,406 | Jul 31, 2025 |
| Jul 31, 2025 | AGX ARGAN INC | SOpen-market sale Common Stock | -1,604 | $242.77 | $389k | 7,802 | Jul 31, 2025 |
| Jul 30, 2025 | AGX ARGAN INC | MOption exercise Option to Purchase Common Stockderivative | -3,500 | $36.78 | $129k | 16,000 | Jul 31, 2025 |
| Apr 30, 2025 | AGX ARGAN INC | SOpen-market sale Common Stock | -1,565 | $152.32 | $238k | 7,802 | May 1, 2025 |
| Jan 8, 2025 | AGX ARGAN INC | SOpen-market sale Common Stock | -2,000 | $150.00 | $300k | 9,367 | Jan 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.